Immune surveillance as a rationale for immunotherapy?

Area of Science:

• Oncology
• Immunology
• Cancer Vaccine Development

Background:

• Pathogen vaccines are primarily prophylactic, unlike therapeutic cancer vaccines.
• Tumorigenesis involves complex immune system interactions, necessitating approaches from autoimmunity research.
• Significant barriers exist for active cancer immunotherapy, including tumor burden, immunosuppression, stromal interactions, and immune escape.

Purpose of the Study:

• To explore challenges in developing effective cancer vaccines.
• To propose alternative strategies for tumor immunotherapy.
• To reframe the objective of tumor immunotherapy from breaking to reshaping immune tolerance.

Main Methods:

• Review of existing challenges in active cancer immunotherapy.
• Analysis of immune tolerance mechanisms in the context of cancer.
• Conceptualization of immunomodulators targeting innate and adaptive immunity interfaces.

Main Results:

• Active immunotherapy for cancer faces substantial hurdles including tumor-induced immunosuppression and immune escape.
• Immune tolerance is an active, threshold-dependent process that can be modulated.
• Adjuvant immunotherapy, post-tumor mass removal, is a necessary consideration.

Conclusions:

• Effective cancer immunotherapy requires addressing tumor-specific immune suppression.
• Reshaping or repairing immune tolerance, not breaking it, is a more viable objective.
• The future of cancer immunotherapy may lie in immunomodulators rather than traditional vaccines.